In addition, the ability of exoSTING to focus its activity within the tumor microenvironment while minimizing systemic exposure may reduce the risk of side effects, making it an attractive option for enhancing the therapeutic index of STING agonists (46). The gene discussed is STING1; the disease is neoplasm.